Document is current
Any future updates will be listed below
-
Authors
Carbone, Antonino https://orcid.org/0000-0003-2211-639X
Borok, Margaret
Damania, Blossom
Gloghini, Annunziata https://orcid.org/0000-0002-7226-1942
Polizzotto, Mark N. https://orcid.org/0000-0002-6446-183X
Jayanthan, Raj K.
Fajgenbaum, David C. https://orcid.org/0000-0002-7367-8184
Bower, Mark https://orcid.org/0000-0002-4077-6351
- License Information
-
More Information
Article History
Accepted: 6 October 2021
First Online: 25 November 2021
Competing interests
: M. Bow. received speaker honoraria from Gilead sciences, BMS, MSD, Janssen and ViiV. M.N.P. received speaker honoraria from Gilead Sciences and research funding from BMS, Celgene, Janssen and ViiV (to the institution, outside the area of the submitted work). D.C.F. has received research funding from EUSA Pharma and Janssen Pharmaceuticals, the study drug from Pfizer for a clinical trial of sirolimus in Castleman disease, and two provisional patents pending on the diagnosis and treatment of Castleman disease. The other authors declare no competing interests.
